blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1608353

EP1608353 - PREVENTION AND TREATMENT OF BREAST CANCER WITH 4-HYDROXY TAMOXIFEN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.03.2015
Database last updated on 03.10.2024
Most recent event   Tooltip08.07.2016Lapse of the patent in a contracting state
New state(s): HU, TR		published on 10.08.2016  [2016/32]
Applicant(s)For all designated states
Besins Healthcare Luxembourg SARL
67 boulevard Grande-Duchesse Charlotte
1331 Luxembourg / LU
[2011/02]
Former [2005/52]For all designated states
LABORATOIRES BESINS INTERNATIONAL
3, rue du Bourg l'Abbé
75003 Paris / FR
Inventor(s)01 / SALIN-DROUIN, Dominique
32, rue des Gatines
F-91370 Verrières-le-Buisson / FR
02 / WEPIERRE, Jacques
1, rue Valoise
F-77166 Grisy Suisnes / FR
03 / ROUANET, Philippe
154, rue des Quatre Seigneurs
F-34090 Montpellier / FR
 [2005/52]
Representative(s)Brown, David Leslie
Haseltine Lake Kempner LLP
Redcliff Quay
120 Redcliff Street
Bristol BS1 6HU / GB
[N/P]
Former [2014/05]Brown, David Leslie
Haseltine Lake LLP
Redcliff Quay
120 Redcliff Street
Bristol BS1 6HU / GB
Former [2012/36]Cabinet Plasseraud
52, rue de la Victoire
75440 Paris Cedex 09 / FR
Former [2008/35]Nargolwalla, Cyra
Cabinet Plasseraud 52 rue de la Victoire
75440 Paris Cedex 09 / FR
Former [2005/52]Nargolwalla, Cyra
Cabinet Plasseraud 65/67, rue de la Victoire
75440 Paris Cedex 09 / FR
Application number, filing date03785958.415.12.2003
[2005/52]
WO2003EP15029
Priority number, dateUS20030458963P01.04.2003         Original published format: US 458963 P
[2005/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004087123
Date:14.10.2004
Language:EN
[2004/42]
Type: A1 Application with search report 
No.:EP1608353
Date:28.12.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 14.10.2004 takes the place of the publication of the European patent application.
[2005/52]
Type: B1 Patent specification 
No.:EP1608353
Date:30.04.2014
Language:EN
[2014/18]
Search report(s)International search report - published on:EP14.10.2004
ClassificationIPC:A61K9/00, A61K31/138, A61K31/137, A61K47/14
[2013/13]
CPC:
A61K31/137 (EP); A61K31/138 (EP); A61K47/14 (EP);
A61K9/0014 (EP); A61P35/00 (EP); A61K47/38 (EP)
Former IPC [2005/52]A61K31/138, A61P35/00, A61K47/14, A61K47/38
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/52]
TitleGerman:VORBEUGUNG UND BEHANDLUNG VON BRUSTKREBS MIT 4-HYDROXY TAMOXIFEN[2005/52]
English:PREVENTION AND TREATMENT OF BREAST CANCER WITH 4-HYDROXY TAMOXIFEN[2005/52]
French:PREVENTION ET TRAITEMENT DU CANCER DU SEIN A L'AIDE DE 4-HYDROXY TAMOXIFENE[2005/52]
Entry into regional phase01.09.2005National basic fee paid 
01.09.2005Designation fee(s) paid 
01.09.2005Examination fee paid 
Examination procedure02.09.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
01.09.2005Examination requested  [2005/52]
25.01.2006Despatch of a communication from the examining division (Time limit: M06)
03.08.2006Reply to a communication from the examining division
27.02.2007Despatch of a communication from the examining division (Time limit: M04)
15.06.2007Reply to a communication from the examining division
30.05.2008Despatch of a communication from the examining division (Time limit: M04)
22.09.2008Reply to a communication from the examining division
28.02.2012Despatch of a communication from the examining division (Time limit: M04)
04.07.2012Reply to a communication from the examining division
11.11.2013Communication of intention to grant the patent
19.03.2014Fee for grant paid
19.03.2014Fee for publishing/printing paid
Divisional application(s)EP08103007.4  / EP1952810
EP08103014.0  / EP1941871
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.01.2006
Opposition(s)02.02.2015No opposition filed within time limit [2015/15]
Fees paidRenewal fee
24.11.2005Renewal fee patent year 03
29.11.2006Renewal fee patent year 04
26.11.2007Renewal fee patent year 05
27.11.2008Renewal fee patent year 06
26.10.2009Renewal fee patent year 07
20.10.2010Renewal fee patent year 08
14.10.2011Renewal fee patent year 09
07.11.2012Renewal fee patent year 10
07.10.2013Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.12.2003
AT30.04.2014
BE30.04.2014
CY30.04.2014
CZ30.04.2014
DK30.04.2014
EE30.04.2014
FI30.04.2014
MC30.04.2014
RO30.04.2014
SE30.04.2014
SI30.04.2014
SK30.04.2014
TR30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
[2016/32]
Former [2016/27]AT30.04.2014
BE30.04.2014
CY30.04.2014
CZ30.04.2014
DK30.04.2014
EE30.04.2014
FI30.04.2014
MC30.04.2014
RO30.04.2014
SE30.04.2014
SI30.04.2014
SK30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
Former [2015/36]AT30.04.2014
BE30.04.2014
CY30.04.2014
CZ30.04.2014
DK30.04.2014
EE30.04.2014
FI30.04.2014
RO30.04.2014
SE30.04.2014
SI30.04.2014
SK30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
Former [2015/11]AT30.04.2014
BE30.04.2014
CY30.04.2014
CZ30.04.2014
DK30.04.2014
EE30.04.2014
FI30.04.2014
RO30.04.2014
SE30.04.2014
SK30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
Former [2015/10]AT30.04.2014
BE30.04.2014
CY30.04.2014
CZ30.04.2014
DK30.04.2014
EE30.04.2014
FI30.04.2014
SE30.04.2014
SK30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
Former [2015/08]AT30.04.2014
BE30.04.2014
CY30.04.2014
DK30.04.2014
FI30.04.2014
SE30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
Former [2015/02]AT30.04.2014
CY30.04.2014
FI30.04.2014
SE30.04.2014
BG30.07.2014
GR31.07.2014
PT01.09.2014
Former [2014/51]AT30.04.2014
CY30.04.2014
FI30.04.2014
SE30.04.2014
BG30.07.2014
GR31.07.2014
Former [2014/50]CY30.04.2014
FI30.04.2014
SE30.04.2014
BG30.07.2014
GR31.07.2014
Former [2014/49]CY30.04.2014
FI30.04.2014
BG30.07.2014
Former [2014/48]CY30.04.2014
BG30.07.2014
Former [2014/47]CY30.04.2014
Cited inInternational search[X]US4973755  (GRAFE INGOMAR [DE], et al) [X] 1-22 * abstract * * column 1, line 6 - line 31 * * column 10, line 1 - line 40 *;
 [X]US4919937  (MAUVAIS-JARVIS PIERRE [FR], et al) [X] 1-22 * the whole document *;
 [XA]US5904930  (FISCHER WILFRIED [DE], et al) [X] 1-12,22 * the whole document * [A] ;
 [XA]WO9736570  (S W PATENTVERWERTUNGS GES M B [AT], et al) [X] 10-14,22 * page 8, line 15 - line 25 * * page 9, line 26 - page 11, line 9 * * examples 4,5 * [A] ;
 [X]  - MAUVAIS-JARVIS P ET AL, "TRANS-4 HYDROXYTAMOXIFEN CONCENTRATION AND METABOLISM AFTER LOCAL PERCUTANEOUS ADMINISTRATION TO HUMAN BREAST", CANCER RESEARCH, (1986), vol. 46, no. 3, ISSN 0008-5472, pages 1521 - 1525, XP009030099 [X] 1-11 * abstract * * page 1522, column L, paragraph 2 * * page 1525, column L, line 30 - line 32 * * page 1525, column L, line 42 - line 49 *
 [X]  - KUTTENN F ET AL, "Basis for percutaneous administration of antiestrogens in breast pathology", CONTRACEPTION FERTILITE SEXUALITE 1991 FRANCE, (1991), vol. 19, no. 2, ISSN 0980-3904, pages 165 - 171, XP001180881 [X] 1-9 * abstract * * page 169 - page 170 *
 [PX]  - SIMONY-LAFONTAINE I ET AL, "Neoadjuvant percutaneous-4-hydroxytamoxifen decreases breast cancer cell proliferation: A prospective randomizediimage analysis Study.", ANALYTICAL CELLULAR PATHOLOGY, 9th International Conference on Applied Genomics-European Society for Analytical Cellular Pathology/;Amsterdam, Netherlands; October 01-04, 2003, (2003), vol. 25, no. 5-6, ISSN 0921-8912, pages 258 - 259, XP009030125 [PX] 1-11 * the whole document *
ExaminationWO2004054557
 WO2004054558
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.